Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:LTUSNASDAQ:OTLKNASDAQ:RPTXNYSE:VHAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLTUSLotus Pharmaceuticals$0.01-12.7%$0.01$0.00▼$0.01$18.25M-2.4860,362 shs627 shsOTLKOutlook Therapeutics$1.82-1.1%$1.60$0.87▼$9.25$61.09M0.31800,759 shs302,531 shsRPTXRepare Therapeutics$1.47+1.2%$1.30$0.89▼$4.29$62.92M0.84253,068 shs37,176 shsVHAQViveon Health Acquisition$11.00$11.00$0.00▼$12.48$62.26M-0.112 shs99 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLTUSLotus Pharmaceuticals-12.66%+38.00%+15.00%-12.66%+130.00%OTLKOutlook Therapeutics-1.09%-4.21%+4.00%+15.92%-75.89%RPTXRepare Therapeutics+1.17%-0.20%+12.41%+33.36%-63.23%VHAQViveon Health Acquisition0.00%0.00%0.00%0.00%+10.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AOTLKOutlook Therapeutics1.4054 of 5 stars3.41.00.00.01.90.00.6RPTXRepare Therapeutics2.4075 of 5 stars3.33.00.00.01.62.50.6VHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLTUSLotus Pharmaceuticals 0.00N/AN/AN/AOTLKOutlook Therapeutics 2.80Moderate Buy$9.60427.47% UpsideRPTXRepare Therapeutics 2.50Moderate Buy$4.50206.75% UpsideVHAQViveon Health Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LTUS, VHAQ, RPTX, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025OTLKOutlook TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $21.005/20/2025OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/ARPTXRepare Therapeutics$1.07M58.64N/AN/A$5.03 per share0.29VHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLTUSLotus Pharmaceuticals-$20KN/A0.00∞N/AN/AN/AN/AN/AOTLKOutlook Therapeutics-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%8/13/2025 (Estimated)RPTXRepare Therapeutics-$93.80M-$3.01N/AN/AN/A-99.76%-40.87%-35.07%N/AVHAQViveon Health Acquisition-$610KN/A0.00∞N/AN/AN/AN/AN/ALatest LTUS, VHAQ, RPTX, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025OTLKOutlook Therapeutics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/AVHAQViveon Health AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLTUSLotus PharmaceuticalsN/AN/AN/AOTLKOutlook TherapeuticsN/A0.320.64RPTXRepare TherapeuticsN/A6.456.45VHAQViveon Health AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLTUSLotus PharmaceuticalsN/AOTLKOutlook Therapeutics11.20%RPTXRepare Therapeutics85.09%VHAQViveon Health Acquisition22.14%Insider OwnershipCompanyInsider OwnershipLTUSLotus PharmaceuticalsN/AOTLKOutlook Therapeutics4.80%RPTXRepare Therapeutics11.50%VHAQViveon Health Acquisition75.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableOTLKOutlook Therapeutics2033.57 million30.48 millionOptionableRPTXRepare Therapeutics18042.89 million33.33 millionOptionableVHAQViveon Health Acquisition25.66 million1.40 millionNot OptionableLTUS, VHAQ, RPTX, and OTLK HeadlinesRecent News About These CompaniesViveon Health Acquisition CorpNovember 21, 2024 | investing.comClearday, Inc. (CLRD)September 6, 2024 | finance.yahoo.comClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - UpdatedMay 3, 2024 | finance.yahoo.comClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future SuccessMay 2, 2024 | finance.yahoo.comViveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination ProcessFebruary 28, 2024 | finanznachrichten.deVIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESSFebruary 27, 2024 | globenewswire.comNYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)February 21, 2024 | finance.yahoo.comViveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSEDecember 27, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)December 22, 2023 | tmcnet.comSan Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas.November 13, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS)October 24, 2023 | finance.yahoo.comVHAQ-R Viveon Health Acquisition Corp.September 23, 2023 | seekingalpha.comViveon Health Acquisition Received Audit Opinion With Going Concern ExplanationSeptember 15, 2023 | marketwatch.comVIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATIONSeptember 15, 2023 | finance.yahoo.comViveon Healthcare Increases Consideration Offered to Clearday ShareholdersSeptember 5, 2023 | finance.yahoo.comSPAC Viveon ups merger consideration for Clearday to $500MAugust 29, 2023 | msn.comViveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger AgreementAugust 29, 2023 | finance.yahoo.comVIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILINGApril 25, 2023 | finance.yahoo.comViveon Health Acquisition Corp. (VHAQ-RT)April 18, 2023 | finance.yahoo.com(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to MarketApril 12, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTUS, VHAQ, RPTX, and OTLK Company DescriptionsLotus Pharmaceuticals OTCMKTS:LTUS$0.0069 0.00 (-12.66%) As of 06/13/2025 11:39 AM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.Outlook Therapeutics NASDAQ:OTLK$1.82 -0.02 (-1.09%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.84 +0.01 (+0.82%) As of 06/13/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Repare Therapeutics NASDAQ:RPTX$1.47 +0.02 (+1.17%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.44 -0.03 (-1.84%) As of 06/13/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.Viveon Health Acquisition NYSE:VHAQ$11.00 0.00 (0.00%) As of 01/30/2025Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
